Trade Mark Attorney
BScLLB(Hons), MIP, GDLP
Bachelor of Science (Molecular Genetics),
Bachelor of Laws (with Honours),
Graduate Diploma of Legal Practice, Masters of Industrial Property
Naomi is listed in IAM Patent 1000 as one of Australia's leading patent litigators. Underpinning Naomi’s legal work is a deep understanding of the pharma/biopharma industries, resulting from first hand experience and knowledge as VP of IP in-house at global pharma giants, and Partner of a top-tier international law firm.
Naomi Pearce is a strategic, commercially astute, patent lawyer, patent attorney and trade mark attorney, with over 23 years experience supporting global pharma/biopharma, and a background in molecular biology/biochemistry.
Naomi's industry focus is generic and biosimilar medicines, and she has an extensive list of generic and biosimilar clients from around the world.
Naomi's clients value her creative, pragmatic solutions to legal/patent “problems”, and she is recognised by industry as a leader in patent strategies.
Naomi is the founding Principal of Pearce IP, which commenced in 2017. Naomi trained at leading law firm Ashurst (1997 - 2002), spent 13 years leading the biopharma IP teams of Pfizer (Hospira) and Mylan (2002 – 2015) including at VP of IP level, is a former Partner of Big Law’s K&L Gates where she Co-Chaired the K&L Gates global Pharma/Biopharma Industry Group.
Drawing from her considerable in-house experience, Naomi builds elegant market entry strategies for her clients which align with their commercial objectives, and are anchored with legal and technical excellence.
Naomi is a biosimilars IP trailblazer. Naomi’s decade of global biosimilars responsibility at Pfizer (Hospira) and at executive level at Mylan put her ahead of the curve on issues relating to the global development and launch of biosimilars. Naomi continues to lead her peers on biosimilars IP strategies and has many current active matters relating to biosimilar mAb products.
Naomi manages AU patent litigations in the Australian Courts and is a leader in multi jurisdictional litigations.
In her former life in-house, Naomi managed multiple US Hatch Waxman litigation, US PMNOC strategies, CA PMNOC proceedings, patent litigations in AU, HK, UK, DE, NE, NZ, PO, IE (among other regions), and patent oppositions before EPO, AU and NZ. Naomi's clients use her global litigation experience to assist them manage global litigations with many moving parts, and to coordinate overseas litigations.
Naomi was the first Chair of the Legal Working Group of the Generic and Biosimilar Medicines Association of Australia (GBMA), and for many years was actively involved with various committees of the European Generics Association (EGA), the US Generic Pharmaceuticals Association (GPhA), and the US Cooalition for a Competitive Pharmaceutical Market (CCPM).
Naomi is a regular international speaker on IP issues relating to small molecule and biosimilar medicines.